BR112018008928A2 - um método ex vivo para testar a capacidade de resposta celular de populações de células primárias a um fármaco ou combinação de fármacos - Google Patents

um método ex vivo para testar a capacidade de resposta celular de populações de células primárias a um fármaco ou combinação de fármacos

Info

Publication number
BR112018008928A2
BR112018008928A2 BR112018008928-1A BR112018008928A BR112018008928A2 BR 112018008928 A2 BR112018008928 A2 BR 112018008928A2 BR 112018008928 A BR112018008928 A BR 112018008928A BR 112018008928 A2 BR112018008928 A2 BR 112018008928A2
Authority
BR
Brazil
Prior art keywords
drug
cell populations
primary
tumor
testing
Prior art date
Application number
BR112018008928-1A
Other languages
English (en)
Inventor
Antonio BALLESTEROS NOBELL Juan
Bennett Teresa
Primo Ramos Daniel
Prospero Ghia Paolo
Belén ESPINOSA OQUILLAS Ana
Gorrochategui Guillén Julián
Robles Mateos Alicia
Hernández Campo Pilar
Original Assignee
Vivia Biotech, S.L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivia Biotech, S.L filed Critical Vivia Biotech, S.L
Publication of BR112018008928A2 publication Critical patent/BR112018008928A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

a invenção aqui apresentada se refere a um método para produzir um ambiente artificial de populações de células primárias, particularmente um ambiente tumoral artificial de populações de células tumorais primárias e seu uso em um método ex vivo para testar a capacidade de resposta celular de populações de células tumorais primárias a um fármaco ou fármacos. o método da invenção compreende a incubação das células tumorais primárias com o ambiente tumoral artificial e o fármaco ou fármacos e análise da resposta das populações de células tumorais primárias. a incubação das células tumorais primárias com o ambiente tumoral artificial aumenta a viabilidade das referidas células tumorais e/ou induz níveis maiores de proliferação de células tumorais e, consequentemente, aumenta a sensibilidade e precisão do teste em relação ao(s) fármaco(s) examinado(s).
BR112018008928-1A 2015-11-04 2016-11-04 um método ex vivo para testar a capacidade de resposta celular de populações de células primárias a um fármaco ou combinação de fármacos BR112018008928A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250687P 2015-11-04 2015-11-04
US62/250,687 2015-11-04
PCT/EP2016/076690 WO2017077046A1 (en) 2015-11-04 2016-11-04 An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs

Publications (1)

Publication Number Publication Date
BR112018008928A2 true BR112018008928A2 (pt) 2019-04-30

Family

ID=57421814

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008928-1A BR112018008928A2 (pt) 2015-11-04 2016-11-04 um método ex vivo para testar a capacidade de resposta celular de populações de células primárias a um fármaco ou combinação de fármacos

Country Status (14)

Country Link
US (1) US20190212325A1 (pt)
EP (1) EP3371595B1 (pt)
JP (1) JP6774685B2 (pt)
KR (1) KR20180070603A (pt)
CN (1) CN108351345B (pt)
AU (1) AU2016348722A1 (pt)
BR (1) BR112018008928A2 (pt)
CA (1) CA3003347A1 (pt)
CL (1) CL2018001138A1 (pt)
HK (1) HK1258451A1 (pt)
IL (1) IL259013A (pt)
MX (1) MX2018005228A (pt)
SG (1) SG11201803461RA (pt)
WO (1) WO2017077046A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111089977A (zh) * 2019-12-30 2020-05-01 浙江科途医学科技有限公司 一种利用类器官检测溶瘤病毒有效性的方法
EP4271995A1 (en) * 2020-12-31 2023-11-08 Elephas Biosciences Corporation Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue
CN117192115A (zh) * 2023-11-03 2023-12-08 赛德特(北京)生物工程有限公司 检测t淋巴细胞免疫活性的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008352548B2 (en) * 2008-03-12 2014-12-04 Sanofi Pasteur Vaxdesign Corporation Disease model incorporation into an artificial immune system (AIS)
TW201024733A (en) * 2008-09-26 2010-07-01 Sanofi Aventis Methods for determining sodium-proton-exchanger ligand efficiency
US20120213706A1 (en) * 2009-04-15 2012-08-23 University Of Medicine And Dentistry Of New Jersey Reconstituted tumor microenvironment for anticancer drug development
MX2011012267A (es) * 2009-05-19 2012-04-11 Vivia Biotech Sl Metodos para proveer pruebas de medicina personalizadas ex vivo en cuanto a neoplasmas hematologicos.
WO2014035668A1 (en) * 2012-08-28 2014-03-06 The Brigham And Women's Hospital, Inc. Functional assay for cancer recurrence and malignant potential
WO2015042450A1 (en) * 2013-09-20 2015-03-26 Pak Chorom Cellular cis-co-culture systems and methods

Also Published As

Publication number Publication date
EP3371595B1 (en) 2019-12-25
MX2018005228A (es) 2018-08-15
CA3003347A1 (en) 2017-05-11
JP6774685B2 (ja) 2020-10-28
EP3371595A1 (en) 2018-09-12
IL259013A (en) 2018-06-28
AU2016348722A1 (en) 2018-05-17
CN108351345A (zh) 2018-07-31
CN108351345B (zh) 2021-11-30
CL2018001138A1 (es) 2018-10-12
US20190212325A1 (en) 2019-07-11
HK1258451A1 (zh) 2019-11-15
WO2017077046A1 (en) 2017-05-11
KR20180070603A (ko) 2018-06-26
SG11201803461RA (en) 2018-05-30
JP2018533728A (ja) 2018-11-15

Similar Documents

Publication Publication Date Title
Fiorillo et al. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
De Luca et al. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells
Jiang et al. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment
AU2018261622A1 (en) Diagnostic advanced glycation end-product antibodies
ES2729341T3 (es) Método para un ensayo de selección de fármacos basado en células y uso del mismo
BR112017004773A2 (pt) biomarcadores para avaliar câncer de mama
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
BR112017007965A2 (pt) método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
BR112018009071A8 (pt) método para preparar uma amostra, composição homogenizada, métodos para gerar dados, para tratar uma doença, de identificação de um marcador, para determinar o prognóstico de um câncer, para determinar um perfil fenotípico, para armazenar a composição homogenizada, para preparar uma amostra de tecido e preparar a composição homogenizada
BR112013027124A2 (pt) método e sistema para analisar características de tecido
AR084723A1 (es) microARN (miARN) COMO BIOMARCADOR PARA LA IDENTIFICACION DEL CANCER COLORRECTAL FAMILIAR Y NO FAMILIAR
BR112018008928A2 (pt) um método ex vivo para testar a capacidade de resposta celular de populações de células primárias a um fármaco ou combinação de fármacos
MX2018013621A (es) Metodo, matriz y uso de estos.
CA2815892C (en) Analytical methods and arrays for use in the same
CY1120731T1 (el) Θεραπευτικη αγωγη κατα του καρκινου
BR112012026219A2 (pt) método diagnósticos para glaucoma
Lorito et al. Glucose metabolic reprogramming of ER+ breast cancer in acquired resistance to the CDK4/6 inhibitor palbociclib
AU2018275891A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
WO2019074615A3 (en) In vitro methods for skin therapeutic compound discovery using skin age biomarkers
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
Cui et al. Chemotherapy induces ovarian cancer cell repopulation through the caspase 3-mediated arachidonic acid metabolic pathway
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
PE20180930A1 (es) Composiciones y metodos para la vigilancia activa del cancer de prostata
BR112019003147A2 (pt) uso de um marcador, métodos para identificar uma célula-tronco neural de mamífero e/ou uma célula progenitora neural de mamífero, para isolar uma célula-tronco neural de mamífero e/ou uma célula progenitora neural de mamífero, para determinar se um composto de teste modula uma diferenciação de célula-tronco neural de mamífero e/ou de célula progenitora neural de mamífero in vitro, para produzir uma população isolada de células de mamífero in vitro, para tratar doença ou dano e/ou prevenir e proteger contra dano no sistema nervoso em um indivíduo, para tratar um distúrbio mental ou comportamental em um indivíduo e para determinar as características de uma área danificada ou doente do snc em um paciente, cultura celular in vitro, cultura em suspensão, marcador para células-tronco neurais de mamífero e/ou para células progenitoras neurais de mamífero, e, composição.

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements